UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

Early Phase 1

Recruiting

• Conditions: CD19-positive Relapsed or Refractory B-cell Malignancies
• Interventions: Biological: UTAA09 cells for infusion; Drug: Fludarabine; Drug: Cyclophosphamide

• Registration Number: NCT06092047
• Lead Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Brief Summary

This study is designed for exploring the preliminary safety and efficacy of the recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell hematolymphatic malignancies.

Detailed Description

A single arm open-label clinical study is designed to prelinarily determine the safety, efficacy, the ratio of CD19-positive cells in peripheral blood and cell kinetics after administration of UTAA09 injection in patients with CD19-positive relapsed/refractory B-cell hematolymphatic malignancies. All subjects will receive UTAA09 cells infusion.

Primary objective: explore the preliminary safety and efficacy of UTAA09 injection in patients with CD19-positive relapsed/refractory B-cell line hematolymphatic malignancies.

Secondary objectives:

1. explore the distribution, amplification and survival of UTAA09 cells in vivo after administration of UTAA09 injection;

2. explore the ratio of CD19-positive cells in peripheral blood after administration of UTAA09 injection.

Study Timeline

• Study Start: 2023-10-01
• Study First Submitted: 2023-10-07
• Study First Submitted QC: 2023-10-13
• Study First Posted: 2023-10-23
• Status Verified: 2024-05
• Last Update Submitted: 2025-05-13
• Last Update Posted: 2025-05-16
• Primary Completion: 2026-07
• Study Completion: 2028-04

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Patients aged between 3~70 (including cut-off values), regardless of gender and race;

2. Expected survival time>12 weeks;

3. ECOG score 0-2;

4. CD19-positive relapsed/refractory B-cell hematolymphatic malignancies;

5. Liver and kidney function, cardiopulmonary function meet the following requirements:

   1. Creatinine ≤ 1.5 ULN;
   2. Left ventricular ejection fraction ≥ 45%;
   3. blood oxygen saturation>91%;
   4. Total bilirubin ≤ 1.5 × ULN； ALT and AST ≤ 2.5 × ULN;

6. Be able to understand the trial and have signed the informed consent.

Exclusion Criteria

1. Those with graft-versus-host disease (GVHD) or requiring long-term systemic immunosuppressants;
2. Malignant tumors other than CD19-positive hematologic malignancies within 5 years prior to screening, except adequately treated cervical carcinoma in situ, basal cell or squamous epithelial cell skin cancer, local prostate cancer after radical resection, and breast ductal carcinoma in situ after radical resection;
3. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer outside the normal reference range; Those who are positive for hepatitis C virus (HCV) antibodies and positive for hepatitis C virus (HCV) RNA in peripheral blood; Human immunodeficiency virus (HIV) antibody positive person; Positive for cytomegalovirus (CMV) DNA testing; those who test positive for syphilis;
4. Serious heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (NYHA classification ≥ III), and serious arrhythmia;
5. Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment;
6. Within 7 days before screening, there is active infection or uncontrollable infection requiring systemic treatment (except for mild genitourinary system infection and upper respiratory tract infection);
7. Pregnant or lactating women, female subjects who planned to conceive within 1 year of cell infusion or male subjects whose partner planned pregnancy within 1 year of their cell infusion;
8. Screening participants (except for inhalation or local use) who were receiving systemic steroid treatment within 7 days before screening or who were judged by the investigator to require long-term systemic steroid therapy during treatment;
9. Participated in other clinical studies within 3 month before screening;
10. There was evidence of central nervous system involvement at participant screening;
11. Conditions that the investigators considered unsuitable for enrollment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
UTAA09 cells for infusion	UTAA09 cells for infusion	Off-the-shelf γδT cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day-7\~Day-2.
UTAA09 cells for infusion	Fludarabine	Off-the-shelf γδT cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day-7\~Day-2.
UTAA09 cells for infusion	Cyclophosphamide	Off-the-shelf γδT cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day-7\~Day-2.

Primary Outcome Measures

Name	Time	Method
Assessment of the safety after UTAA09 injection treatment	About 2 years	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.
Evaluation of the efficacy after UTAA09 injection treatment	About 3 months	3-month total response rate (ORR) which includes CR, CRi, and PR will be assessed.

Secondary Outcome Measures

Name	Time	Method
Assessment of pharmacokinetic (about Cmax)	About 2 years	Assessment of the peak Plasma Concentration (Cmax) of UTAA09 cells amplified in peripheral blood after administration.
Assessment of pharmacokinetic (about Tmax)	About 2 years	Assessment of the time to reach the highest concentration (Tmax) of UTAA09 cells amplified in peripheral blood after administration.
Assessment of pharmacokinetic (about AUC0-28d)	About 2 years	Assessment of the Area under the plasma concentration versus time curve (AUC) for 28 days after UTAA09 cells administration.
Assessment of pharmacokinetic (about AUC0-90d)	About 2 years	Assessment of the Area under the plasma concentration versus time curve (AUC) for 90 days after UTAA09 cells administration.
Evaluation of Pharmacodynamic	About 2 years	To determine the depletion of peripheral blood CD19-positive B cells at each time point, the concentration of CAR-γδT-associated serum cytokine (CRP, IL-6, etc.).
To evaluate the efficacy (Overall Survival)	About 2 years	Defined as the time from the start of UTAA09 injection therapy to patient death (due to any cause).
To evaluate the efficacy (Duration Of Response)	About 2 years	Defined as the time from the first tumor assessment of CR or PR, CR or CRi to the first assessment of disease recurrence or progression or death (due to any cause).
To evaluate the efficacy (Progression Free Survival)	About 2 years	Defined as the time from the start of UTAA09 injection therapy to the first disease progression or recurrence or death due to any cause.

Trial Locations

Locations (1)

The First Affiliated Hospital of USTC (AnHui Provincial Hospital); 🇨🇳 Hefei, Anhui, China